Interstitial Lung Disease Trial, Recruiting (NCT05567133)

Interstitial Lung Disease Trial, Recruiting NCT05567133 Sponsor: University of California, San Francisco Condition: Interstitial Lung Disease

Printed from Voxsanity (voxsanity.com.au) — NCT05567133 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Interstitial Lung Disease

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

You are 18 years of age or older and have been diagnosed with sarcoidosis
Your diagnosis was confirmed through a tissue biopsy (a small sample of tissue examined in a lab), and other possible causes of your symptoms have been ruled out, following established medical guidelines from 1999

Who may not be able to join:

You are unable to go through the study procedures, as decided by the trial doctor
You are currently pregnant or breastfeeding
You have certain other health conditions that could affect the study's test results, such as a weakened immune system disorder (like common variable immunodeficiency), HIV infection, or an autoimmune disease
You have another lung condition alongside sarcoidosis, such as hypersensitivity pneumonitis (lung inflammation caused by inhaled substances) or idiopathic pulmonary fibrosis (scarring of the lungs of unknown cause)
Your red blood cell levels are very low (below 25% on a specific blood test called a hematocrit) (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 23 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Laura Koth, University of California, San Francisco

Phone: 4155144369

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT05567133

Sponsor: University of California, San Francisco

Phase: Not Applicable

Status: Recruiting

Condition: Interstitial Lung Disease

Trial contact: 4155144369

More information: https://clinicaltrials.gov/study/NCT05567133

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

You are 18 years of age or older and have been diagnosed with sarcoidosis
Your diagnosis was confirmed through a tissue biopsy (a small sample of tissue examined in a lab), and other possible causes of your symptoms have been ruled out, following established medical guidelines from 1999

Who may not be able to join:

You are unable to go through the study procedures, as decided by the trial doctor
You are currently pregnant or breastfeeding
You have certain other health conditions that could affect the study's test results, such as a weakened immune system disorder (like common variable immunodeficiency), HIV infection, or an autoimmune disease
You have another lung condition alongside sarcoidosis, such as hypersensitivity pneumonitis (lung inflammation caused by inhaled substances) or idiopathic pulmonary fibrosis (scarring of the lungs of unknown cause)
Your red blood cell levels are very low (below 25% on a specific blood test called a hematocrit) (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 23 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

University of California, San Francisco

Registry

ClinicalTrials.gov

Start date

10 January 2023

Est. completion

30 March 2030

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Mean Change in Forced Vital Capacity in Liters

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov